Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ra Capital Management Revealed Stake in Dicerna Pharmaceuticals Inc (DRNA) After Deerfield and Brookside

Ra Capital Management, a fund managed by Peter Kolchinsky, disclosed, in a new filing with the Securities and Exchange Commission, that it owns 2.43 million shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), equivalent to 14.6% of the common stock.

Peter Kolchinsky

In another filing the fund revealed that of 2.43 million shares, 1.43 million shares were obtained via conversion from Series C preferred stock, held by Ra Capital prior to the company’s IPO. At the same time, the fund purchased a total of 1.0 million shares at a price of $15 apiece. Peter Kolchinsky is a director of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), and he might exercise his control received from this position.

Yesterday, James E. Flynn’s Deerfield Management, disclosed holding 2.42 million common shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). James Flynn is a large shareholder at Dicerna. In another filing Brookside Capital, managed by Bain Capital also revealed that it holds 2.34 million shares of the company.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), is a biopharmaceutical company, and treats rare inherited diseases in liver and for cancer. The company went public a couple of days ago, offering 6.0 million shares at a price of $14.0 per share.

The stock has been favored amongst insiders Stephen Hoffman, director at Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), purchased 200,000 shares from the IPO, and currently owns around 1.73 million shares.

RA Capital Management invests in companies with promising drugs and technologies. A day before the fund revealed in a filing that it initiated a stake in Furiex Pharmaceuticals Inc (NASDAQ:FURX), and now holds 750,000 shares.

At the end of September 2013, RA Capital Management held 10.42 million shares of Dyax Corp. (NASDAQ:DYAX), with 7.45% of its equity portfolio invested in the company’s stock.

Disclosure: none

Recommended Reading:

Diamond Hill Capital Management Top Picks: United Technologies Corp. (UTX), American International Group Inc. (AIG) & More

Deerfield Management Reports New Stake in KaloBios Pharmaceuticals Inc (KBIO)

Hedge Fund Highlights: Warren Buffett, Bill Ackman & Richard Gerson

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!